Skip to main content

Table 4 Comparison of adjusted change in ESA resistance index per month over study follow-up among baseline oxidative stress and inflammatory marker quartiles

From: Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients

 

Change in ESA Resistance Index per Montha

Marker

Quartile 1

Quartile 2

Quartile 3

Quartile 4

Quartile 4 to 1 Comparison P-value

Overall trend P-valueb

F2-Isoprostanes (ng/ml/month)

.76 (.07,1.45)

2.54 (−3.64,8.73)

1.65 (−4.62,7.93)

5.95 (−.45,12.35)

0.07

0.63

Isofurans (ng/ml/month)

.65 (−.02,1.32)

6.87 (.83,12.92)

2.41 (−3.74,8.56)

6.26 (.19,12.33)

0.04

0.99

hsCRP (mg/l/month)

.15 (−.53,.84)

2.15 (−3.96,8.27)

4.99 (−1.12,11.09)

8.27 (2.17,14.38)

0.008

0.59

IL-6 (pg/ml/month)

.52 (−.15,1.19)

2.89 (−3.05,8.84)

2.7 (−3.35,8.75)

8.79 (2.83,14.75)

0.004

0.83

  1. a Adjusted for age, sex, race, body mass index, etiology of end stage renal disease, diabetes status, transferrin saturation (serum iron/total iron binding capacity), Kt/V, serum parathyroid hormone, study visit, and treatment assignment
  2. b P-value for trend over biomarker quartiles